Jessica Wojciechowski1,2,3, Michael D Wiese2,3, Susanna M Proudman4,5, David J R Foster1,2,3, Richard N Upton1,2,3. 1. Australian Centre for Pharmacometrics, University of South Australia, Adelaide. 2. Sansom Institute for Health Research, University of South Australia, Adelaide. 3. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide. 4. Rheumatology Unit, Royal Adelaide Hospital, Adelaide. 5. Discipline of Medicine, University of Adelaide, Adelaide, Australia.
Abstract
AIMS: Composite indices for quantifying rheumatoid arthritis (RA) disease activity such as the 28-joint disease activity score (DAS28) are comprised of single parameters ('metrics') in various combinations. Population modelling methods were used to evaluate single metrics for their ability to reflect changes in disease activity with a view to understanding and improving composite indices. METHODS: A total of 11 single metrics of RA disease activity (tender and swollen joint counts, acute phase reactants and global health, pain and physical function assessments) were obtained from 203 patients with recent onset RA. Participants received combination disease-modifying anti-rheumatic drugs (DMARDs) according to a treat-to-target approach with a pre-defined protocol for treatment intensification. Models describing each metric's magnitude and variability of change from baseline to a single 'treated' state in the population were developed using nonmem(®) . Measures that displayed uniformly large changes between states across the population were ranked higher in terms of discriminatory capacity. RESULTS: Joint counts demonstrated a greater ability to discriminate changes in RA disease activity than others. Correlations between metrics demonstrated that erythrocyte sedimentation rate (ESR) had limited relationships with others for baseline scores and changes in RA disease activity (r generally < 0.2). However it appeared to be important in describing changes for those individuals where ESR levels were initially elevated. CONCLUSION: It appears unlikely that a single group of metrics may be suitable to capture disease activity changes across all RA patients and defining the most appropriate metric(s) for individual patients will be an important area of future research.
AIMS: Composite indices for quantifying rheumatoid arthritis (RA) disease activity such as the 28-joint disease activity score (DAS28) are comprised of single parameters ('metrics') in various combinations. Population modelling methods were used to evaluate single metrics for their ability to reflect changes in disease activity with a view to understanding and improving composite indices. METHODS: A total of 11 single metrics of RA disease activity (tender and swollen joint counts, acute phase reactants and global health, pain and physical function assessments) were obtained from 203 patients with recent onset RA. Participants received combination disease-modifying anti-rheumatic drugs (DMARDs) according to a treat-to-target approach with a pre-defined protocol for treatment intensification. Models describing each metric's magnitude and variability of change from baseline to a single 'treated' state in the population were developed using nonmem(®) . Measures that displayed uniformly large changes between states across the population were ranked higher in terms of discriminatory capacity. RESULTS: Joint counts demonstrated a greater ability to discriminate changes in RA disease activity than others. Correlations between metrics demonstrated that erythrocyte sedimentation rate (ESR) had limited relationships with others for baseline scores and changes in RA disease activity (r generally < 0.2). However it appeared to be important in describing changes for those individuals where ESR levels were initially elevated. CONCLUSION: It appears unlikely that a single group of metrics may be suitable to capture disease activity changes across all RApatients and defining the most appropriate metric(s) for individual patients will be an important area of future research.
Authors: D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte Journal: Ann Rheum Dis Date: 1992-02 Impact factor: 19.103
Authors: A A Stenger; M A Van Leeuwen; P M Houtman; G A Bruyn; F Speerstra; B C Barendsen; E Velthuysen; M H van Rijswijk Journal: Br J Rheumatol Date: 1998-11
Authors: Susanna M Proudman; Helen I Keen; Lisa K Stamp; Anita T Y Lee; Fiona Goldblatt; Oliver C Ayres; Maureen Rischmueller; Michael J James; Catherine L Hill; Gillian E Caughey; Leslie G Cleland Journal: Semin Arthritis Rheum Date: 2007-03-27 Impact factor: 5.532
Authors: S M M Verstappen; J W G Jacobs; M J van der Veen; A H M Heurkens; Y Schenk; E J ter Borg; A A M Blaauw; J W J Bijlsma Journal: Ann Rheum Dis Date: 2007-05-22 Impact factor: 19.103
Authors: Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton Journal: Br J Clin Pharmacol Date: 2016-04-07 Impact factor: 4.335
Authors: Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde Journal: Ann Rheum Dis Date: 2010-03-09 Impact factor: 19.103
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Jonathan Kay; Olga Morgacheva; Susan P Messing; Joel M Kremer; Jeffrey D Greenberg; George W Reed; Ellen M Gravallese; Daniel E Furst Journal: Arthritis Res Ther Date: 2014-02-03 Impact factor: 5.156
Authors: Jessica Wojciechowski; Michael D Wiese; Susanna M Proudman; David J R Foster; Richard N Upton Journal: Br J Clin Pharmacol Date: 2016-04-07 Impact factor: 4.335